Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

CLL1+CD33 CAR-T

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Guangzhou Bio-gene Technology, Zhejiang University

Drug class:

CD33-targeted CAR-T immunotherapy, CLL-1-targeted CAR-T immunotherapy

Related drugs:

‹

CD33 CAR T cells (0)

CD33PAN CAR T (0)

CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells (0)

CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T (0)

Dual CD33/CLL1 CAR T (0)

Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells (0)

anti-CD33 CAR T (0)

multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)

CD371-YSNVZ-IL18 CAR T cells (0)

CD33 CAR T cells (0)

CD33PAN CAR T (0)

CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells (0)

CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T (0)

Dual CD33/CLL1 CAR T (0)

Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells (0)

anti-CD33 CAR T (0)

multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)

CD371-YSNVZ-IL18 CAR T cells (0)

›